About absci corp - ABSI
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
ABSI At a Glance
Absci Corp.
18105 SE Mill Plain Boulevard
Vancouver, Washington 98683
| Phone | 1-360-949-1041 | Revenue | 2.80M | |
| Industry | Biotechnology | Net Income | -115,183,000.00 | |
| Sector | Health Technology | Employees | 140 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ABSI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 170.483 |
| Price to Book Ratio | 2.791 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.995 |
| Enterprise Value to Sales | 120.843 |
| Total Debt to Enterprise Value | 0.016 |
ABSI Efficiency
| Revenue/Employee | 20,000.00 |
| Income Per Employee | -822,735.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.013 |
ABSI Liquidity
| Current Ratio | 6.57 |
| Quick Ratio | 6.57 |
| Cash Ratio | 6.338 |
ABSI Profitability
| Gross Margin | -319.357 |
| Operating Margin | -4,454.214 |
| Pretax Margin | -4,111.214 |
| Net Margin | -4,113.679 |
| Return on Assets | -53.585 |
| Return on Equity | -62.501 |
| Return on Total Capital | -59.144 |
| Return on Invested Capital | -61.123 |
ABSI Capital Structure
| Total Debt to Total Equity | 2.799 |
| Total Debt to Total Capital | 2.722 |
| Total Debt to Total Assets | 2.451 |
| Long-Term Debt to Equity | 1.385 |
| Long-Term Debt to Total Capital | 1.347 |